Luis and Henry, I've seen this situation before. That's why I've felt that release of the the 2 critical raw numbers is important to keep people honest (the treated versus the placebo). This is even more important in lidak's case with the history of the previous phase 3 study. You will notice that 90% of the time when a company is vague with numbers, that it turns out they are hiding something,,but sometimes this is not the case. The only reason I stuck with this company this long is that I could not detect a contradiction in their press releases and when talking to IR. (Ususally, they trip up).
Objectively, we have to seriously consider the likely situation that lidakol does NOT work. There are 2 possible outcomes, but in both situations, if Lidak does not release the information before the opening on Friday, they are only helping the crooks (the shortsellers who obviously knew the BMY was getting out).
1). Lidakol works. The crooks who are shortselling on inside info. will then buy the stock of the people panic selling. They will make money on the downside and the upside when the news comes out that lidakol works. Lidak can stop this by releasing the data.
2). Lidakol does NOT work. This would imply that lidak is despicable. Stocks can be shorted through 3rd parties. Of course, this may be someone through BMY.
Remember, that Lidak claims that they did not release the info at the request of BMY (with whom they did this study). Now that BMY is out, what is the reason for continuing to withhold data. Release it and people can make a decision based on the numbers.
Lidak may feel in their own minds that their policy is fine and they won't bend just because some insiders have an advantage. But policy is based on reality, and reality has changed and certain people are taking advantage of their policy, and giving lidak a very bad reputation. If the results are really good, then lidak should do what the other straightforward companies do,,,and..........................
Luis, I hope this does not become an example of why we have to have the numbers, and not double-talk. By the way, to get off this junk, look at Igen, Sepr, and Lgnd. They have similar or better potential than ligand, and they release info. Also in better financial shape and are still very cheap. Also Cytc. These are my favorates, in that order. Lidak was my 5th favorate. But putting it that high had to do with my subjective opinion that I had formed of that company, based on talking to the people there. Here's to hoping that I can tell what people are like, but sometimes there is nothing like facts. Here's to hoping Lidak will release them, especially if they are good. I think they have a definite obligation to do so at this point (BEFORE the open on Friday) or the lawyers will be all over them. |
